Organon on June 3 officially launched through a spinoff from Merck as the only global health company of its size, with a singular vision: “[T]o make a better and healthier every day for every woman.”
The company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines. Headquartered in Jersey City, Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees.
“Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly-traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable growth and value,” said Merck President Rob Davis in a prepared statement.
With a majority-female leadership team, the company will have offices across the globe, including one in Shoreditch, London. Organon’s products will serve people in more than 140 countries, with nearly 80% of its approximately $6.5 billion in annual revenue generated outside the U.S.
Organon plans to explore new opportunities and partnerships across its three main pillars: Women’s health, biosimilars and established brands.
Organon has a dedicated team focusing on improving access to contraceptive and fertility products, and a comprehensive education and training program to help women and health care professionals understand the choices available to them.
Building on its current growth business, this is a dynamic market with multiple launch opportunities in the coming years and a core area of growth with the potential to deliver value to both Organon, the National Health Service and patients in the U.K.
The Established Brands portfolio will be reinvigorated to maximize market-leading, well-known brands that span key therapy areas such as cardiovascular, respiratory, pain, bone and dermatology.
Organon’s R&D philosophy is to build a business around patient needs, with the goal of identifying and advancing health care options for women that enable them to live their best lives every day. The company’s extensive global capabilities in clinical development and patient safety, regulatory and medical affairs make it well-positioned to identify promising drugs, diagnostics, and devices with the greatest potential to impact women’s health.